Cardiff OncologyCRDF +0.76%48 Cyclically Adjusted PS Ratio is 4.91 as of Jul. 13, 2026, which is 16% below its 10-year median of 5.86. GuruFocus rates CRDF with a GF Score™ of 48/100 and a GF Value™ of $1.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 539 Biotechnology companies, Cardiff Oncology ranks better than 55.29% on this metric.
The historical rank and industry rank for Cardiff Oncology's Cyclically Adjusted PS Ratio or its related term are showing as below:
CRDF'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 1.41 Med: 5.86 Max: 19.75
Current: 4.87
During the past years, Cardiff Oncology's highest Cyclically Adjusted PS Ratio was 19.75. The lowest was 1.41. And the median was 5.86.
CRDF's Cyclically Adjusted PS Ratio is ranked better than 55.29% of 539
companies
in the Biotechnology industry
Industry Median: 5.83
vs CRDF: 4.87
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Cardiff Oncology's adjusted revenue per share data for the three months ended in Mar. 2026 was $0.001. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.27 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Cardiff Oncology (NAS:CRDF) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Cardiff Oncology Cyclically Adjusted PS Ratio Related Terms
Cardiff Oncology Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Cardiff Oncology's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cardiff Oncology Cyclically Adjusted PS Ratio Chart
CRDF vs MAIA, TELO, OSTX: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Cardiff Oncology's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiff Oncology Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Cardiff Oncology's Cyclically Adjusted PS Ratio falls into.
Cardiff Oncology Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Cardiff Oncology's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 4.91 mean?
Cardiff Oncology (CRDF) has a Cyclically Adjusted PS Ratio of 4.91 as of Jul. 13, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. This is 16% below median its historical median of 5.86. Over the past decade, Cardiff Oncology's Cyclically Adjusted PS Ratio has ranged from 1.41 to 19.75. According to the industry distribution chart, Cardiff Oncology ranks #241 out of 539 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Cardiff Oncology's Cyclically Adjusted PS Ratio too high?
Cardiff Oncology's current Cyclically Adjusted PS Ratio of 4.91 is 16% below median its 10-year median of 5.86. Over the past 10 years, this metric has ranged from a low of 1.41 to a high of 19.75. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.83. Cardiff Oncology's value of 4.91 is 15.8% below this industry median. Based on the distribution chart, Cardiff Oncology ranks #241 out of 539 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cardiff Oncology has a GF Score™ of 48/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cardiff Oncology's Cyclically Adjusted PS Ratio compare to MAIA and TELO?
According to the Biotechnology industry distribution chart, Cardiff Oncology ranks #241 out of 539 companies for Cyclically Adjusted PS Ratio. This puts Cardiff Oncology in the upper half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.83. Cardiff Oncology's value of 4.91 is 15.8% below this benchmark. Historically, Cardiff Oncology's own Cyclically Adjusted PS Ratio has ranged from 1.41 to 19.75 over the past decade. While the company's 10-year median is 5.86 vs. the industry median of 5.83, Cardiff Oncology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.83, based on 539 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cardiff Oncology's current Cyclically Adjusted PS Ratio of 4.91 is 15.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cardiff Oncology and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cardiff Oncology's current Cyclically Adjusted PS Ratio is 4.91, which is 16% below median its own 10-year median of 5.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiff Oncology stock overvalued right now?
Based on GuruFocus' analysis, Cardiff Oncology (CRDF) is currently considered Fairly Valued. The stock's GF Value™ is $1.41, compared to a current price of $1.33 — trading 6% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 4.91, which is 16% below median its 10-year median of 5.86 and 15.8% below the Biotechnology industry median of 5.83. Cardiff Oncology's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Cardiff Oncology (CRDF), the current Cyclically Adjusted PS Ratio is 4.91 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cardiff Oncology (CRDF) Overvalued in 2026?
Based on GuruFocus' analysis, Cardiff Oncology stock appears to be undervalued.
The current stock price of $1.33 is trading 6% below its estimated GF Value™ of $1.41.
GuruFocus considers Cardiff Oncology to be Fairly Valued.
Key valuation signals for CRDF:
Cyclically Adjusted PS Ratio: 4.91 (16% below median its 10-year median of 5.86)
GF Value™: $1.41 vs. price of $1.33 (6% below fair value)
Industry Position: 15.8% below the Biotechnology median (#241 of 539)
No single metric tells the full story. See the CRDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
48GF Score
Get the complete analysis for CRDF
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRDF has been successfully added to your 
